CareDxCDNA
CDNA
About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Employees: 650
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
78% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 50
49% more call options, than puts
Call options by funds: $763K | Put options by funds: $512K
0.87% more ownership
Funds ownership: 97.95% [Q3] → 98.83% (+0.87%) [Q4]
5% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 43
3% less funds holding
Funds holding: 215 [Q3] → 208 (-7) [Q4]
30% less capital invested
Capital invested by funds: $1.61B [Q3] → $1.13B (-$477M) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 3 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
36%
upside
Avg. target
$30
68%
upside
High target
$40
126%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
HC Wainwright & Co. Yi Chen 38% 1-year accuracy 63 / 167 met price target | 41%upside $25 | Neutral Maintained | 3 Mar 2025 |
Stephens & Co. Mason Carrico 18% 1-year accuracy 5 / 28 met price target | 126%upside $40 | Overweight Reiterated | 27 Feb 2025 |
Wells Fargo Brandon Couillard 14% 1-year accuracy 3 / 21 met price target | 36%upside $24 | Equal-Weight Upgraded | 15 Jan 2025 |
Financial journalist opinion
Based on 5 articles about CDNA published over the past 30 days
Neutral
Business Wire
3 days ago
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA). CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October 28, 2021, the Company disclosed that it was the subject of two federal investigations by the U.S. Department.
Neutral
Business Wire
1 week ago
CI Global Asset Management Announces Securityholder Approval of Fund Mergers
TORONTO--(BUSINESS WIRE)---- $CDNA #CIFinancial--CI Global Asset Management has received securityholder approval to proceed with the merger of six mutual funds and two ETFs into other mandates.
Neutral
PRNewsWire
2 weeks ago
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW YORK and NEW ORLEANS , March 14, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Neutral
Business Wire
3 weeks ago
CareDx Launches Two Expanded Indications for AlloSure Testing Services
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. Both indicatio.
Neutral
Business Wire
4 weeks ago
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA). CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October 28, 2021, the Company disclosed that it was the subject of two federal investigations by the U.S. Department.
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for February 27th
BCS, CDNA, PGR, EZPW and EVER have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2025.
Neutral
Seeking Alpha
1 month ago
CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Bill Bonello - Craig-Hallum Andrew Cooper - Raymond James Mason Carrico - Stephens Eduardo Martinez - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good afternoon, everyone.
Positive
Zacks Investment Research
1 month ago
CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Business Wire
1 month ago
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenue of $86.6 million, increased 32% year-over-year Testing services revenue of $63.8 million, increased 37% year-over-year, and testing services volume of approximately 45,500, increased 14% year-over-year GAAP net income of $87.7 million, non-GAAP net income of $10.7 million, and positive adjusted E.
Neutral
Business Wire
1 month ago
CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation brought by a competitor. The District Court ruled that the patents asserted against CareDx are invalid. The Court reached this determination because the pate.
Charts implemented using Lightweight Charts™